Onco-Innovations begins nanoparticle work with Dalton

Mr. Thomas O'Shaughnessy reports ONCO-INNOVATIONS COMMENCES ACTIVITIES TO MANUFACTURE NANOPARTICLE FORMULATION WITH DALTON PHARMA TO SUPPLY PRECLINICAL ANIMAL STUDIES Dalton Pharma Services has commenced activities to manufacture Onco-Innovations Ltd.'s proprietary nanoparticle formulation, also know as PEO-b-PBz-CL, a key component of the company's novel drug delivery platform which is designed for use in conjunction with Onco's proprietary polynucleotide kinase phosphatase (PNKP) inhibitor. The manufacturing initiative is intended to generate the nanoparticle material required to advance preclinical studies. The production campaign will include process optimization and scale-up activities to establish reproducible methods for the synthesis of PEO-b-PBz-CL, while ensuring that the formulation meets quality specifications for purity, molecular weight and residual solvent levels. Dalton has already demonstrated initial feasibility at the 10-gram scale and will now focus on reducing residual catalyst content and scaling production to 100 grams, followed by a demonstration batch at the 350-gram scale. These activities are designed to provide sufficient quantities of nanoparticle material for formulation development, while also generating the analytical data necessary to support regulatory filings and the eventual transition to good manufacturing practice (GMP) manufacturing. By engaging Dalton, Onco benefits from the technical expertise and regulatory experience of one of Canada's leading contract development and manufacturing organizations. Dalton's work will provide a comprehensive development package, including full analytical characterization and process documentation, to ensure a smooth path toward clinical readiness of the nanoparticle-formulated platform. "Advancing the nanoparticle formulation demonstrates will help inform our next phase of development, advancing our pathway toward the clinical opportunities we are determined to reach," stated Thomas O'Shaughnessy, chief executive officer of Onco-Innovations. About Onco-Innovations Ltd. Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours. We seek Safe Harbor.